Frequency Therapeutics, Inc.
FREQ
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company... Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments that unlock the body's inherent capacity for regeneration to restore impaired functions. Their "Progenitor Cell Activation" approach leverages small molecules to stimulate progenitor cells within the body, encouraging the formation of new, functional tissues. The company's flagship product candidate, FX-322, is currently in Phase IIa clinical trials, aiming to address the fundamental cause of sensorineural hearing loss. Beyond this, Frequency is also advancing therapies for various degenerative diseases, including multiple sclerosis, and ailments impacting muscles, the gastrointestinal system, skin, and bones. For the development and commercialization of FX-322, the company holds a license and collaboration agreement with Astellas Pharma Inc. Additionally, it maintains collaboration and licensing agreements with esteemed organizations such as Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Founded in 2014, Frequency Therapeutics, Inc. is headquartered in Lexington, Massachusetts.
